Topas Therapeutics signs multi-year research and option agreement with Lilly focused on immune tolerance

22-08-2017 09:28

Topas Therapeutics GmbH (Topas), a Hamburg, Germany-based private company, today announced that it has signed a multi-year agreement with Eli Lilly and Company (Lilly) to collaborate in the field of antigen-specific tolerance induction with an initial focus on external antigens thought to induce inflammation and/or autoimmune disease.

PDF-file 60.2kb

Dutch version - French version - German version